# Title

 Food and Drugs. PART 320â€”BIOAVAILABILITY AND BIOEQUIVALENCE REQUIREMENTS


# ID

 CFR-2018-title21-vol5.Pt. 320


# Structured Analysis Summary

| Type        | Values                                                                                                                                                                                   |
|:------------|:-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Constraints | ['maximum', 'exceeds', 'least', 'after', 'prior to', 'equal to', 'minimum', 'less than', 'at least', 'greater than', 'within', 'later than']                                             |
| Duration    | ['2.0 year', '15.0 day', '5.0 year', '7.0 day', '30.0 minute']                                                                                                                           |
| Condition   | ['subject to', 'until', 'as soon as', 'where', 'not subject to', 'when', 'provided that', 'unless', 'if']                                                                                |
| Entities    | ['Rockville, MD', 'Upon', 'Information', 'Dose', 'Paragraph', 'Bioequivalence', 'Basis', 'Research, Office', 'New', 'Food', 'Certain', 'Followup', 'Relevant', 'Research', 'Critically'] |


# Structured Analysis With Context

 


## Constraints

| Constraints   | Context                                                                                                                         |
|:--------------|:--------------------------------------------------------------------------------------------------------------------------------|
| within        | (2) The application agrees to submit,  within the time specified by FDA, either: (i) Evidence                                   |
| at least      | a drug product determined to be effective for at least one indication in a Drug Efficacy Study Implementation                   |
| within        | active moiety to the bloodstream for systemic distribution within the body; or (ii) An in vitro test                            |
| least         | This approach is the  least accurate, sensitive, and reproducible of the general approaches                                     |
| greater than  | intended to be used interchangeably; or (3) Has greater than anticipated potential toxicity related to pharmacokinetic or other |
| after         | or the therapeutic moiety needs to be established after  single-dose administration and in certain instances                    |
| after         | or the therapeutic moiety needs to be established after  single-dose administration and in certain instances                    |
| after         | ingredient or therapeutic moiety that is poorly absorbed after oral administration, it may be necessary to compare              |
| at least      | metabolite(s), measured in the blood or urine; or at least                                                                      |
| at least      | half-life of decay of the acute pharmacological effect. at least                                                                |
| at least      | area under the curve for a time period at least three times the half-life of the active drug                                    |
| at least      | area under the curve for a time period at least three times the half-life of decay of the                                       |
| after         | product and the reference material to be compared after repeated administration to determine steady-state levels of the         |
| at least      | half-life of decay of the acute pharmacological effect. at least                                                                |
| at least      | half-life of decay of the acute pharmacological effect. at least                                                                |
| equal to      | the fraction of the dose absorbed and is equal to the corresponding &#8220;zero to infinity&#8221; area under the               |
| maximum       | be made with sufficient frequency to demonstrate a maximum effect and a lack of significant difference between                  |
| prior to      | protocol for the study to FDA for review prior to  the initiation of the study.                                                 |
| maximum       | in normal subjects or patients where either the maximum single or total daily dose exceeds that specified                       |
| exceeds       | either the maximum single or total daily dose exceeds that specified in the labeling of the drug                                |
| exceeds       | where either the single or total daily dose exceeds that specified in the labeling of the drug                                  |
| later than    | as soon as possible but in no case later than 15 calendar days after becoming aware of its                                      |
| after         | in no case later than 15 calendar days after  becoming aware of its occurrence.                                                 |
| later than    | as soon as possible but in no case later than 7 calendar days after becoming aware of its                                       |
| after         | in no case later than 7 calendar days after  becoming aware of its occurrence.                                                  |
| later than    | as soon as possible, but in no case later than  15 calendar days after receiving the request.                                   |
| after         | in no case later than 15 calendar days after  receiving the request.                                                            |
| less than     | exhibit a narrow therapeutic ratio, e.g., there is less than a 2-fold difference in median lethal dose (LD50)                   |
| less than     | exhibit a narrow therapeutic ratio, e.g., there is less than a 2-fold difference in median lethal dose (LD50)                   |
| minimum       | have less than a 2-fold difference in the minimum  toxic concentrations and                                                     |
| minimum       | have less than a 2-fold difference in the minimum  toxic concentrations and                                                     |
| less than     | ingredient has a low solubility in water, e.g., less than 5 milligrams per 1 milliliter, or, if dissolution                     |
| exceeds       | fluids required to dissolve the recommended dose far exceeds the volume of fluids present in the stomach                        |
| less than     | one or more such products is slow, e.g., less than 50 percent in 30 minutes when tested using                                   |
| greater than  | high ratio of excipients to active ingredients, e.g., greater than  5 to 1.                                                     |
| less than     | therapeutic moiety, or its precursor is poor, e.g., less than 50 percent, ordinarily in comparison to an intravenous            |
| at least      | requirement shall be maintained by the manufacturer for at least 2 years after the expiration date of the                       |
| after         | by the manufacturer for at least 2 years after the expiration date of the batch and submitted                                   |
| after         | part 54 of this chapter for 2 years after  the date of approval of the application.                                             |
| at least      | sample shall be retained for a period of at least 5 years following the date on which the                                       |
| at least      | sample shall be retained for a period of at least 5 years following the date on which the                                       |


## Duration

| Duration    | Context                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:------------|:--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 15.0 day    | (d) A bioavailability or bioequivalence study in humans other than one described in paragraphs (a) through (c) of this section is exempt from the requirements of part 312 of this chapter if the following conditions are satisfied:                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
|             |               (1) If the study is one described under &#167;&#8201;320.38(b) or &#167;&#8201;320.63, the person conducting the study, including any contract research organization, must retain reserve samples of any test article and reference standard used in the study and release the reserve samples to FDA upon request, in accordance with, and for the period specified in, &#167;&#8201;320.38;                                                                                                                                                                                                                                                                                             |
|             |               (2) An in vivo bioavailability or bioequivalence study in humans must be conducted in compliance with the requirements for institutional review set forth in part 56 of this chapter, and informed consent set forth in part 50 of this chapter; and                                                                                                                                                                                                                                                                                                                                                                                                                                      |
|             |               (3) The person conducting the study, including any contract research organization, must notify FDA and all participating investigators of any serious adverse event, as defined in &#167;&#8201;312.32(a), observed during the conduct of the study as soon as possible but in no case later than 15 calendar days after becoming aware of its occurrence.                                                                                                                                                                                                                                                                                                                                |
| 7.0 day     | Each report must bear prominent identification of its contents, i.e., &#8220;bioavailability/bioequivalence safety report.&#8221; The person conducting the study, including any contract research organization, must also notify FDA of any fatal or life-threatening adverse event from the study as soon as possible but in no case later than 7 calendar days after becoming aware of its occurrence.                                                                                                                                                                                                                                                                                               |
| 15.0 day    | Relevant followup information to a bioavailability/bioequivalence safety report must be submitted as soon as the information is available and must be identified as such, i.e., &#8220;Followup bioavailability/bioequivalence safety report.&#8221; Upon request from FDA, the person conducting the study, including any contract research organization, must submit to FDA any additional data or information that the agency deems necessary, as soon as possible, but in no case later than 15 calendar days after receiving the request.                                                                                                                                                          |
| 30.0 minute | (2) The dissolution rate of one or more such products is slow, e.g., less than 50 percent in 30 minutes when tested using either a general method specified in an official compendium or a paddle method at 50 revolutions per minute in 900 milliliters of distilled or deionized water at 37 &#176;C, or differs significantly from that of an appropriate reference material such as an identical drug product that is the subject of an approved full new drug application.                                                                                                                                                                                                                         |
| 2.0 year    | (a) All records of in vivo or in vitro tests conducted on any marketed batch of a drug product to assure that the product meets a bioequivalence requirement shall be maintained by the manufacturer for at least 2 years after the expiration date of the batch and submitted to the Food and Drug Administration on request.                                                                                                                                                                                                                                                                                                                                                                          |
| 2.0 year    | (b) Any person who contracts with another party to conduct a bioequivalence study from which the data are intended to be submitted to FDA as part of an application submitted under part 314 of this chapter shall obtain from the person conducting the study sufficient accurate financial information to allow the submission of complete and accurate financial certifications or disclosure statements required under part 54 of this chapter and shall maintain that information and all records relating to the compensation given for that study and all other financial interest information required under part 54 of this chapter for 2 years after the date of approval of the application. |
| 5.0 year    | Each reserve sample shall be retained for a period of at least 5 years following the date on which the application or supplemental application is approved, or, if such application or supplemental application is not approved, at least 5 years following the date of completion of the bioavailability study in which the sample from which the reserve sample was obtained was used.                                                                                                                                                                                                                                                                                                                |
| 5.0 year    | Each reserve sample shall be retained for a period of at least 5 years following the date on which the application or supplemental application is approved, or, if such application or supplemental application is not approved, at least 5 years following the date of completion of the bioavailability study in which the sample from which the reserve sample was obtained was used.                                                                                                                                                                                                                                                                                                                |
| 5.0 year    | If FDA has not collected or requested delivery of a reserve sample, or if FDA has not collected or requested delivery of any portion of a reserve sample, the applicant or contract research organization shall retain the sample or remaining sample for the 5-year period specified in paragraph (e) of this section.                                                                                                                                                                                                                                                                                                                                                                                 |


## Condition

| Condition      | Context                                                                                                                                             |
|:---------------|:----------------------------------------------------------------------------------------------------------------------------------------------------|
| when           | &#167;&#8201;314.3 of this chapter apply to those terms when  used in this part.                                                                    |
| if             | in paragraphs (a) and (b) of this section if the supplemental application proposes any of the following                                             |
| if             | new indication for use of the drug product, if clinical studies are required to support the new                                                     |
| if             | regimen for a special patient population, e.g., infants, if clinical studies are required to support the new                                        |
| if             | of the requirement for in vivo bioavailability data, if  all of the following conditions are met.                                                   |
| if             | product that is the subject of the application if  not                                                                                              |
| if             | of evidence of in vivo bioavailability or bioequivalence if the drug product meets any of the provisions                                            |
| if             | self-evident based on other data in the application if the product meets one of the following criteria:                                             |
| unless         | a drug product under &#167;&#8201;310.6 of this chapter unless FDA has evaluated the drug product under the                                         |
| if             | or demonstrating the bioequivalence of the drug product if the drug product meets one of the following                                              |
| if             | of evidence of in vivo bioavailability or bioequivalence if waiver is compatible with the protection of the                                         |
| if             | the submission of evidence of in vivo bioavailability if deferral is compatible with the protection of the                                          |
| if             | vivo bioavailability or bioequivalence for any drug product if  the agency determines that any d                                                    |
| if             | vivo bioavailability of a drug product is measured if the product's rate and extent of absorption, as                                               |
| if             | (3) A drug product that d if fers from the reference material in its rate                                                                           |
| if             | drug products will be considered bioequivalent drug products if they are pharmaceutical equivalents or pharmaceutical alternatives whose            |
| when           | of absorption do not show a significant difference when administered at the same molar dose of the                                                  |
| when           | of the active ingredient or active moiety, and, when appropriate, its active metabolite(s), in whole blood, plasma,                                 |
| when           | the urinary excretion of the active moiety, and, when appropriate, its active metabolite(s), are measured as a                                      |
| where          | This method is not appropriate  where urinary excretion is not a significant mechanism of                                                           |
| when           | acute pharmacological effect of the active moiety, and, when appropriate, its active metabolite(s), are measured as a                               |
| if             | metabolite(s), are measured as a function of time if such effect can be measured with sufficient accuracy,                                          |
| when           | described in paragraph (b)(1)(i) of this section only when appropriate methods are not available for measurement of                                 |
| when           | described in paragraph (b)(1)(i) of this section only when appropriate methods are not available for measurement of                                 |
| when           | distribution, this approach may be considered acceptable only when analytical methods cannot be developed to permit use                             |
| when           | distribution, this approach may be considered acceptable only when analytical methods cannot be developed to permit use                             |
| if             | or radiopaque medium; and bronchodilators administered by inhalation if the onset and duration of pharmacological activity are                      |
| if             | in humans of a product at any time if the agency has evidence that the product: (1)                                                                 |
| unless         | be included in an in vivo bioavailability study unless the attending physician determines that there is a                                           |
| unless         | be in comparison to an appropriate reference material unless some other approach is more appropriate for valid                                      |
| unless         | same route as the formulation proposed for marketing unless an alternative or additional route is necessary to                                      |
| if             | the same active drug ingredient or therapeutic moiety, if the new formulation, new dosage form, or new                                              |
| if             | extended release claim is made is to determine if all of the following conditions are met: (i)                                                      |
| subject to     | drug ingredient or therapeutic moiety and that is subject to  an approved full new drug application.                                                |
| subject to     | (iii) A currently marketed extended release drug product  subject to an approved full new drug application containing the                           |
| if             | involving a combination drug product is to determine if the rate and extent of absorption of each                                                   |
| if             | Food and Drug Administration may permit this determination if the pharmacokinetics and the interactions of the active                               |
| where          | Where appropriate or  where necessary to demonstrate the sensitivity of the test,                                                                   |
| if             | product to be tested and the reference material, if it is another drug product, shall be shown                                                      |
| where          | identity, strength, quality, and purity, including potency and, where  applicable, content uniformity, disintegration times, and dissolution rates. |
| unless         | be administered to subjects in the fasting state, unless some other approach is more appropriate for valid                                          |
| unless         | A single-dose study should be crossover in design, unless a parallel design or other design is more                                                 |
| unless         | metabolite(s), measured in the blood or urine; or unless                                                                                            |
| when           | ingredient or therapeutic moiety, or its metabolite(s), measured. when                                                                              |
| unless         | to be based on blood concentration time curves, unless some other approach is more appropriate for valid                                            |
| unless         | to be based on cumulative urinary excretion-time curves, unless some other approach is more appropriate for valid                                   |
| when           | approach is more appropriate for valid scientific reasons. when                                                                                     |
| unless         | the half-life of decay of the pharmacological effect, unless some other approach is more appropriate for valid                                      |
| subject to     | (ii) There is excessive variability in bioavailability from  subject to  subject.                                                                   |
| unless         | A multiple-dose study should be crossover in design, unless a parallel design or other design is more                                               |
| if             | other design is more appropriate for valid scient if ic reasons, and should provide for a drug                                                      |
| if             | is not required to be of crossover design if the study is to establish dose proportionality under                                                   |
| if             | other approach is more appropriate for valid scient if ic reasons, the drug elimination period should be                                            |
| unless         | (3) If a drug elimination period is required,  unless some other approach is more appropriate for valid                                             |
| unless         | Whenever a multiple-dose study is conducted,  unless some other approach is more appropriate for valid                                              |
| when           | Therefore,  when steady-state conditions are achieved, a comparison of blood                                                                        |
| if             | evidence of safety and effectiveness may be required if  needed to establish the clinical sign                                                      |
| when           | concentration if the requirements of &#167;&#8201;320.31 are met. when                                                                              |
| if             | may be given together to produce higher concentration if  the requirements of &#167;&#8201;320.31 are met.                                          |
| if             | approved, non-new chemical entity shall submit an IND if the study is one of the following: (1)                                                     |
| where          | A single-dose study in normal subjects or patients where either the maximum single or total daily dose                                              |
| where          | A multiple-dose study in normal subjects or patients where either the single or total daily dose exceeds                                            |
| if             | the requirements of part 312 of this chapter if the following conditions are satisfied: (1) If the                                                  |
| if             | the requirements of part 312 of this chapter if the following conditions are satisfied: (1) If the                                                  |
| as soon as     | &#167;&#8201;312.32(a), observed during the conduct of the study as soon as possible but in no case later than 15                                   |
| as soon as     | fatal or life-threatening adverse event from the study as soon as possible but in no case later than 7                                              |
| as soon as     | to a bioavailability/bioequivalence safety report must be submitted as soon as the information is available and must be identified                  |
| as soon as     | to a bioavailability/bioequivalence safety report must be submitted as soon as the information is available and must be identified                  |
| not subject to | to establish a bioequivalence requirement for a product not subject to section 505(j) of the act if it finds                                        |
| if             | not subject to section 505(j) of the act if  it finds there is well-documented evidence that spec                                                   |
| when           | Food and Drugs shall consider the following factors, when supported by well-documented evidence, to identify specific pharmaceutical                |
| if             | less than 5 milligrams per 1 milliliter, or, if dissolution in the stomach is critical to absorption,                                               |
| when           | e.g., less than 50 percent in 30 minutes when tested using either a general method specified in                                                     |
| if             | (6) Spec if ic inactive ingredients, e.g., hydrophilic or hydrophobic excipients                                                                    |
| when           | ordinarily in comparison to an intravenous dose, even when it is administered in pure form, e.g., in                                                |
| subject to     | (6) The drug product is  subject to dose dependent kinetics in or near the therapeutic                                                              |
| if             | to withhold distribution of the batch until not if ied by the Food and Drug Administration that                                                     |
| until          | Administration and to withhold distribution of the batch until notified by the Food and Drug Administration that                                    |
| unless         | Administration and found to meet the bioequivalence requirement, unless the public health requires that batch testing be                            |
| if             | the Federal Food, Drug, and Cosmetic Act, or, if bioavailability testing was performed under contract, the contract                                 |
| if             | to a reference oral solution, suspension, or injection. if                                                                                          |
| if             | If the formulation of the test article d if fers from the formulation(s) used in the clinical                                                       |
| where          | and in an area segregated from the area where testing is conducted and with access limited to                                                       |
| if             | the application or supplemental application is approved, or, if such application or supplemental application is not approved,                       |
| if             | or requested delivery of a reserve sample, or if FDA has not collected or requested delivery of                                                     |
| provided that  | third party to provide storage of reserve samples provided that the sponsor of the study has been notified                                          |
| if             | an appropriate, independent third party, and shall not if y in writing the sponsor of the study                                                     |
| if             | the Federal Food, Drug, and Cosmetic Act, or, if bioequivalence testing was performed under contract, the contract                                  |


## Entities

| Entities         | Context                                                                                                                                                |
|:-----------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------|
| Food             | Food  and Drugs.                                                                                                                                       |
| Paragraph        | (iv)  Paragraph (d) of this section does not apply to                                                                                                  |
| Basis            | Basis  for measuring in vivo bioavailability or demonstrating bioequivalence.                                                                          |
| Information      | Information on bioequivalence requirements for specific products is included                                                                           |
| Critically       | Critically ill patients shall not be included in an                                                                                                    |
| Dose             | Dose proportionality of the active drug ingredient or the                                                                                              |
| New              | (e)  New formulations of active drug ingredients or therapeutic moieties                                                                               |
| Food             | (a) The Commissioner of  Food and Drugs strongly recommends that, to avoid the                                                                         |
| Research, Office | and Drug Administration, Center for Drug Evaluation and Research, Office of Clinical Pharmacology, 10903 New Hampshire Ave., Silver                    |
| Research         | and Drug Administration, Center for Drug Evaluation and Research , Division of Bioequivalence (HFD-650), 7500 Standish Pl.,                            |
| Bioequivalence   | Center for Drug Evaluation and Research, Division of Bioequivalence  (HFD-650), 7500 Standish Pl., Rockville, MD 20855-2773.                           |
| Rockville, MD    | Research, Division of Bioequivalence (HFD-650), 7500 Standish Pl., Rockville, MD  20855-2773.                                                          |
| Relevant         | Relevant followup information to a bioavailability/bioequivalence safety report must                                                                   |
| Followup         | and must be identified as such, i.e., &#8220; Followup bioavailability/bioequivalence safety report.&#8221; Upon request from FDA, the                 |
| Upon             | identified as such, i.e., &#8220;Followup bioavailability/bioequivalence safety report.&#8221; Upon request from FDA, the person conducting the study, |
| Food             | The Commissioner of  Food and Drugs shall consider the following factors, when                                                                         |
| Certain          | (4)  Certain physical structural characteristics of the active drug ingredient,                                                                        |


